Francesca De Lorenzo
Helsinki, Finland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Novel PREP ligand, HUP-46, ameliorates behavioral deficits in an alpha-synuclein based Parkinson's disease model.
Journal: Experimental neurology
Published: September 12, 2025
A prolyl oligopeptidase ligand blocks memory deficit in a repeated mild traumatic brain injury model.
Journal: Experimental neurology
Published: May 30, 2025
GDNF reduces fibril-induced early-stage alpha-synuclein pathology after delivery of 20S proteasome inhibitor lactacystin.
Journal: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
Published: November 01, 2024
5-Aminothiazoles Reveal a New Ligand-Binding Site on Prolyl Oligopeptidase Which is Important for Modulation of Its Protein-Protein Interaction-Derived Functions.
Journal: Journal of medicinal chemistry
Published: March 28, 2024
A prolyl oligopeptidase inhibitor reduces tau pathology in cellular models and in mice with tauopathy.
Journal: Science translational medicine
Published: April 12, 2023
CDNF rescues motor neurons in models of amyotrophic lateral sclerosis by targeting endoplasmic reticulum stress.
Journal: Brain : a journal of neurology
Published: September 23, 2022
Removal of proteinase K resistant αSyn species does not correlate with cell survival in a virus vector-based Parkinson's disease mouse model.
Journal: Neuropharmacology
Published: June 28, 2022
Showing 1-8 of 8
Last Updated: 09/26/2026